Condition: Breast Cancer · Sponsor: University of Aberdeen
Cardiotoxicity is heart damage that arises from certain drugs, such as those used for cancer treatment and develops in approximately 10% of patients with breast cancer who are treated with anthracyclines. It has been suggested that sodium-glucose transporter-2 (SGLT2) inhibitors may reduce the damage to the heart caused by anthracycline chemotherapy. The investigators wish to determine whether dapagliflozin (SGLT2 inhibitor) taken daily during chemotherapy will reduce the rate of cardiotoxicity.
This description comes directly from the study's public registry record.
Sylvia Kamya, MBChB · +441224559573 · sylvia.kamya@nhs.scot
Amelia Rudd, PhD · +441224559573 · a.e.rudd@abdn.ac.uk
Always discuss trial participation with your own doctor first.
| Cardiac Research Office, Aberdeen Royal Infirmary | Aberdeen, Aberdeenshire, United Kingdom | Recruiting |
| University of Aberdeen | Aberdeen, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07070765